Lesley Portnoy and Oasmia Pharmaceutical

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/23/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB Investors – Company Announcement - FT.com | Financial Times | 8/7/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB Investors | Business Wire | 8/7/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Oasmia Pharmaceutical AB Investors | Business Wire | 7/31/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150 …

Glancy Prongay & Murray LLP Continues Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) – Company Announcement - FT.com | Financial Times | 7/18/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire , at 310-201-9150 …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Oasmia Pharmaceutical AB Investors (OASM) | Business Wire | 7/12/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150 …